Company focuses resources on its most advanced clinical development programs while reducing early-stage research activities Organizational adjustments include a workforce reduction of approximately 50 ...
Zurich, 23 October 2025. Elixion Biotech emerges from stealth, announcing the in-silico validation of five targets via its ...
The "Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2025" report highlights significant R&D opportunities with over 20 companies and 22 pipeline drugs, focusing on innovative treatments like ...
The Phase 3 data will be presented by Ann Childress, M.D., a leading ADHD specialist and past President of the American ...
In the enterprise sales segment, data chaos is felt especially acutely. The larger the company, the more complex lead management becomes: sources are scattered, information becomes outdated, and ...
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosisTopline data expected in ...
Discover why Bristol-Myers Squibb (BMY) is a strong buy in 2024—undervalued, high dividend, and robust strategies for ...
Discover how data engineer Ravi Kiran builds self-healing, metadata-driven ETL pipelines that cut failures, automate schema ...
Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...
Q3 2025 Earnings Call Transcript October 23, 2025 Knowles Corporation misses on earnings expectations. Reported EPS is $0.33 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback